August 22, 2013
Ms. Linda Cvrkel
Branch Chief
United States Securities and Exchange Commission
Washington, D.C. 20549
Re: GeneLink, Inc.
Form 10-K for the Year Ended December 31, 2012
Filed April 1, 2013
Form 10-Q for the Quarter Ended March 31, 2013
Filed May 15, 2013
File No. 000-30518
Dear Ms. Cvrkel:
This letter is to confirm the discussion between Michael Smith, Sr. VP of Operations at GeneLink, and Claire Erlanger per the SEC Comment Letter received August 8, 2013, GeneLink requested and was granted an additional 10 business days to respond to the letter. The response to the letter and a draft 10-K Amendment will be filed on or before September 6, 2013.
Sincerely,
/s/ Bernard L. Kasten, Jr., M.D.
Dr. Bernard Kasten, Jr. MD
Chief Executive Officer
